Increased CD40 ligand gene expression during human renal and murine islet allograft rejection.
BACKGROUND
The interaction between CD40 and its ligand CD40L is essential for the development and maintenance of vigorous immunity. We have sought to determine: (i) whether a heightened level of CD40L transcripts is evident during acute allograft rejection and (ii) the kinetics of CD40L gene expression during allograft rejection.


METHODS
By using quantitative reverse transcriptase-assisted polymerase chain reaction techniques, we found that heightened CD40L gene expression is a correlate of acute human renal allograft rejection (P<0.01).


RESULTS
In a murine model of MHC-mismatched islet allografts, our results showed that CD40L transcripts were rarely detected at day 2 after transplantation, but were remarkably heightened at day 5 after transplantation. The transcript levels then steadily increased and peaked at the time of rejection.


CONCLUSIONS
These data suggest that therapy aimed at blocking the CD40 to CD40L interaction should be applied during the immediate posttransplant period.
Zheng
X X
XX
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Schachter
A D
AD
Vasconcellos
L
L
Strehlau
J
J
Tian
Y
Y
Shapiro
M
M
Harmon
W
W
Strom
T B
TB
D000818:Animals; D023201:CD40 Ligand; D003921:Diabetes Mellitus, Experimental / Q000235:genetics; D015870:Gene Expression / Q000502:physiology*; D006084:Graft Rejection / Q000235:genetics*; D006801:Humans; D016381:Islets of Langerhans Transplantation / Q000502:physiology*; D016030:Kidney Transplantation / Q000502:physiology*; D007700:Kinetics; D008562:Membrane Glycoproteins / Q000235:genetics*; D051379:Mice; D016133:Polymerase Chain Reaction; D011184:Postoperative Period; D013997:Time Factors; D014158:Transcription, Genetic
D008562:Membrane Glycoproteins; D023201:CD40 Ligand